Consortium

The consortium of EU-AIMS consists of 20 European organisations and 4 organisations from Switzerland, Iceland, and the United States.

Please click on the map for more information about the teams contributing to the project and the respective organisations.

Consortium

Consortium EU_AIMS F. Hoffmann – La Roche King's College London Central Institute of Mental Health Mannheim Radboud University Nijmegen Medical Centre The Chancellor, Masters and Scholars of the University of Cambridge deCode Genetics University Medical Centre Biozentrum, University of Basel Institut Pasteur GABO:mi Gesellschaft für Ablauforganisation :milliarium mbH & Co. KG Max-Planck-Institute for Experimental Medicine European Molecular Biology Laboratory Karolinska Institutet Eli Lilly and Co Ltd Janssen Pharmaceutica NV Institut de Recherches Servier Vifor Pharma Centre for Brain and Cognitive Development, Birkbeck Università Campus Bio-Medico di Roma Autism Speaks Inc. Pfizer Limited Universität Ulm NeuroSpin

The network of EU-AIMS

The pragmatic approach we adopted as our organizational strategy is to align and enhance existing networks and bring leading "hubs" together with linked satellites across the EU. The overall objective is to strengthen coherence and synergies. This will allow us to cost-effectively include individuals and organizations from diverse geographic and cultural backgrounds across Europe. For example we incorporate the patient organization Autism Europe, the COST network in early autism science (40 scientists from over 20 countries (http://www.cost.esf.org/domains_actions/bmbs/Actions/essea)), BASIS (the leading European infant at-risk autism study), and the ECNP paediatric psychopharmacology network (www.ecnp.eu Co-chair Prof. Buitelaar (RUNMC)). Importantly also we link to other international efforts through our partner ASP.